Loma Therapeutics

What Loma Therapeutics does

Loma Therapeutics is a Danish pre-clinical biotech startup founded in 2023 and headquartered in Copenhagen, developing targeted immunotherapies for HPV-positive cancers and persistent HPV infections. The company is built around a single integrated platform that uses replication-deficient adenoviral vectors to deliver nucleotide sequences encoding four full-length HPV antigens, combined with the MHC class II-associated invariant chain (Ii) as a genetic adjuvant to amplify antigen-presenting cell activation and elicit broad cytotoxic (CD8+) and CD4+ T-cell responses against HPV-infected and HPV+ tumor cells. Its lead candidate, Loma001, is initially focused on HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) and is pre-clinically validated in murine models (monotherapy and in combination with cisplatin), non-human primate studies, and human ex vivo PBMC assays, with peer-reviewed publications in Cancer Immunology Research and Cancers.

The company's customer segments are defined by clinical indication rather than commercial buyers: the primary target is patients with HPV+ oropharyngeal cancer (110,000 new cases/year, 25% recurrence rate, projected 60% growth by 2050), with downstream expansion potential to cervical, anal, penile, vaginal, and vulvar HPV+ cancers, as well as pre-cancer HPV infections. Loma is pre-revenue and pre-clinical, with no commercial product on the market; revenue is intended to come through out-licensing, partnership, or direct commercialization of a future HPV+ cancer immunotherapy, and is currently funded entirely by non-dilutive grants and accelerator programs (BioInnovation Institute Venture Lab/Venture House convertible loan, Women TechEU grant, Innovation Fund Denmark Grand Solutions Grant). Go-to-market is partnership-driven and research-led, with clinical advancement enabled through an academic/clinical consortium (Technical University of Denmark, Kingdom Hospital of Denmark).

Name

Loma Therapeutics

Legal name

Loma Therapeutics

Website

https://lomatherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Loma Therapeutics is a Copenhagen-based pre-clinical biotech developing an adenoviral vector-based HPV-targeted immunotherapy (lead candidate Loma001) that delivers four full-length HPV antigens with the Ii genetic adjuvant to elicit broad cytotoxic T-cell responses against HPV+ oropharyngeal and other HPV-induced cancers.

Ownership category

akta.pro rank

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue R&D funding via grants and accelerator programs: Loma Therapeutics is pre-revenue and pre-clinical. Capital is sourced from non-dilutive grants (Innovation Fund Denmark Grand Solutions Grant; WomenTechEU from the European Commission; BII convertible loan) and partner programs. Future commercialization is expected via out-licensing, partnership, or direct sale of an HPV+ cancer immunotherapy, but no revenue stream is currently realized.

Go-to-market motion3 records

Marketing channels6 records

Core offering

Loma Therapeutics is a pre-clinical Danish biotech developing Loma001, an HPV-targeted immunotherapy that uses replication-deficient adenoviral vectors to deliver four full-length HPV antigens combined with the genetic adjuvant Ii to elicit broad CD8+ T cell responses against HPV+ tumors and HPV-infected cells. The lead candidate is initially focused on HPV-induced oropharyngeal (throat) cancer, with planned expansion to other HPV+ cancers (cervical, anal, penile, vaginal, vulvar) and pre-cancer infections. Pre-clinical proof of concept has been demonstrated in mice, non-human primates, and human ex vivo studies, with regulatory and clinical advancement funded through the Innovation Fund Denmark Grand Solutions Grant consortium.

Product overview

Loma Therapeutics operates a single, integrated therapeutic-vaccine platform anchored by its lead candidate Loma001. The underlying Loma HPV-targeted Immunotherapy Platform uses replication-deficient adenoviral vectors to deliver full-length HPV antigens (combined with the genetic adjuvant Ii) into antigen-presenting cells, driving broad and robust cytotoxic CD8+ T cell responses against HPV+ tumors and HPV-infected cells. Loma001 — the platform's lead clinical-stage-bound candidate — is initially focused on HPV-induced oropharyngeal (throat) cancer, with planned expansion to other HPV+ cancers (cervical, anal, penile, vaginal, vulvar) and to pre-cancer infections, positioning Loma as a developer of a single-platform, multi-indication therapeutic HPV vaccine.

Differentiator

Problem solved

Functional benefit

Brands

• Loma001: Loma's lead HPV-targeted immunotherapy candidate targeting four different HPV antigens via replication-deficient viral vectors.

Products and services

• Loma001 Loma001 is Loma Therapeutics' lead HPV-targeted immunotherapy candidate. It targets four different HPV antigens delivered via replication-deficient adenoviral vectors and is augmented by the genetic adjuvant Ii (MHC class II-associated invariant chain), designed to elicit robust and broad CD8+ T cell responses against HPV-infected and HPV+ tumor cells. Initial clinical focus is HPV-positive oropharyngeal (throat) cancer with planned expansion to cervical, anal, penile, vaginal, and vulvar HPV+ cancers.
• Loma HPV-targeted Immunotherapy Platform Foundational technology platform underpinning Loma001 and future candidates. The platform delivers nucleotide sequences encoding a wide range of full-length HPV antigens via replication-deficient viral vectors (adenoviral vector-based vaccines), stimulating antigen-presenting cells to activate diverse anti-HPV cytotoxic (CD8+) T cells that recognize and kill HPV+ tumor cells and HPV-infected cells predisposed to malignant transformation.

Quantifiable outcome

• Reduced tumor growth and increased survival in murine models, both as monotherapy and in combination with cisplatin; increased CD8+ T-cell infiltration into tumors.
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship — co-recipient of grand solutions grant consortium advancing loma001 into clinical development., core — clinical/operational partner for clinical advancement and patient-monitoring program., core — research collaborator on both key pre-clinical publications and linked to scientific co-founders., core — co-author of the cancer immunology research pre-clinical publication; prof. dr. ralf wagner is a co-founder of loma and a board member. and core — co-author on pre-clinical publications; advisor dr. peter j. holst is ass. professor at ucph and co-founder of loma..

• Technical University of Denmark (DTU)flagship — co-recipient of grand solutions grant consortium advancing loma001 into clinical development.Strategic or Co-development Partner · 1 June 2025Project partner on the Grand Solutions Grant (June 2025) — collaborates with Loma Therapeutics and Kingdom Hospital of Denmark to advance Loma001 to clinical stage, generate deeper understanding of immune-dynamics of HPV-positive oropharyngeal cancer, and implement HPV DNA-based monitoring of patients in Eastern Denmark.
• Kingdom Hospital of Denmarkcore — clinical/operational partner for clinical advancement and patient-monitoring program.Strategic or Co-development Partner · 1 June 2025Project partner on the Grand Solutions Grant (June 2025) — collaborates with Loma Therapeutics and DTU to advance Loma001 into clinical stage and to implement an HPV DNA-based monitoring system for all patients cured of primary HPV+ oropharyngeal cancer in the Eastern region of Denmark.
• Hervolutioncore — research collaborator on both key pre-clinical publications and linked to scientific co-founders.Strategic or Co-development Partner · 1 January 2023Co-collaborator on the human ex vivo validation study published in Cancers (DOI: 10.3390/cancers15245863) and co-author on the Cancer Immunology Research pre-clinical paper. CSO Dr. Peter J. Holst of Hervolution is also a co-founder of Loma.
• University of Regensburgcore — co-author of the cancer immunology research pre-clinical publication; prof. dr. ralf wagner is a co-founder of loma and a board member.Strategic or Co-development Partner · 1 January 2022Academic co-author on Loma's pre-clinical proof of concept published in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-22-0174). Prof. Dr. Ralf Wagner, Head of Molecular Microbiology and Virology at University of Regensburg, co-founded Loma and contributes vaccine-design expertise.
• University of Copenhagen (UCPH)core — co-author on pre-clinical publications; advisor dr. peter j. holst is ass. professor at ucph and co-founder of loma.Strategic or Co-development Partner · 1 January 2022Academic co-author on Loma's pre-clinical publication in Cancer Immunology Research. Advisor Dr. Peter J. Holst, CSO of Hervolution and Ass. Professor at UCPH, is a co-founder of Loma providing academic/scientific expertise.

Scale indicators9 records

Expansion highlights5 records

Direct peers

• ISA Pharmaceuticals: Dutch biotech developing ISA101, a synthetic long-peptide therapeutic vaccine targeting HPV16 E6/E7. Most direct competitor to Loma001 in the HPV+ cancer immunotherapy space, with more advanced clinical-stage data but a narrower (2-antigen) targeting approach.
• Transgene: French clinical-stage biotech developing TG4001, a MVA-vectored therapeutic HPV vaccine (HPV16 E6/E7 + IL-2) for HPV+ cancers. Directly comparable therapeutic vaccine approach in the same indication, with clinical-stage data and a pharma partnership (AstraZeneca).
• Nykode Therapeutics: Norwegian clinical-stage biotech developing VB10.16, a DNA-based therapeutic vaccine for HPV16+ cancers. Scandinavian peer using a different delivery platform but targeting the same patient population as Loma, with Phase II data and pharma partnerships already in place.
• Hookipa Pharma: Austrian/US clinical-stage biotech developing HB-201/HB-202, an arenavirus-based immunotherapeutic for HPV16+ cancers. Directly comparable viral-vectored therapeutic vaccine approach for HPV+ oropharyngeal and other HPV+ cancers, with clinical data and a Gilead partnership.
• PDS Biotechnology: US clinical-stage biotech developing Versamune-HPV (PDS0101), a cationic lipid-based therapeutic HPV vaccine for HPV+ cancers including head and neck. Direct competitor in the same indication, currently in Phase II/III combination studies with checkpoint inhibitors.

Broad incumbents

• BioNTech: German mRNA pioneer developing BNT113, an mRNA-based therapeutic HPV16+ cancer vaccine currently in Phase II/III. BioNTech is a much larger, well-capitalized incumbent using a different (mRNA) delivery modality than Loma's adenoviral vector, but directly competing for the same HPV+ cancer indication.
• Moderna: Large US mRNA platform company whose individualized neoantigen program (mRNA-4157/V940, in partnership with Merck) may eventually extend to HPV+ cancers. Indirect competitor with vastly greater resources, GMP scale, and clinical pipeline breadth, but uses a different (mRNA) modality than Loma's adenoviral vector.

Emerging players

• Nouscom: Swiss/Italian clinical-stage biotech developing viral vector-based (adenovirus, MVA) cancer vaccines including HPV-targeted candidates. Comparable viral-vectored vaccine platform with partial overlap in HPV+ cancer indications, though at a more advanced clinical stage.

Others

• Sirion Biotech: German viral vector technology company listed as a co-author on Loma's Cancer Immunology Research pre-clinical publication, contributing adenoviral vector expertise. Adjacent enabling technology partner/supplier to Loma rather than a direct competitor.
• Hervolution: Danish biotech collaborator on Loma's pre-clinical studies (Cancers and Cancer Immunology Research publications). Hervolution's CSO Dr. Peter J. Holst is also a co-founder of Loma, creating a closely linked scientific/research relationship rather than direct commercial competition.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/loma-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Loma Therapeutics